US 8,524,747 B2 · Pharmaceutical compositions

Abstract

The object of the present invention is to provide a pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB. The pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB contains DTCM glutarimide of the Formula (I) as an effective ingredient, thereby being able to inhibit nitric oxide (NO) production and prostaglandin production.

Claims1

Dependent claims

A method for treating a disease mediated by iNOS or COX-2, comprising the step of administering to a patient suffering from the disease an effective amount of the compound of Formula (I):

wherein n is an integer of 1 to 24, and
wherein the disease is osteoarthritis.

Dependencies are inferred from the claim text.

Facts

Application

13/000,442Filed 25 Jun 2009

Priority

JP 2008-16629025 Jun 2008

Published

US 2011/0213001 A11 Sep 2011

Granted

3 Sep 2013

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07D 211/88
Oxygen atoms: attached in positions 2 and 6, e.g. glutarimide
A61K 31/45
Non condensed piperidines, e.g. piperocaine: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis
A61P 25/00
Drugs for disorders of the nervous system

Abstract

Claims1

Dependent claims

A method for treating a disease mediated by iNOS or COX-2, comprising the step of administering to a patient suffering from the disease an effective amount of the compound of Formula (I):

wherein n is an integer of 1 to 24, and
wherein the disease is osteoarthritis.

Dependencies are inferred from the claim text.

Pharmaceutical compositions

Life of this patent

Abstract

Claims1

Pharmaceutical compositions

Life of this patent

Abstract

Claims1